All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?
Bookmark this article
During the 4th European CAR T-Cell Meeting, the ALL Hub was pleased to speak with Daniel Chen, University College Hospitals, London, UK. We asked, How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?
How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?
Chen begins by highlighting the increased recognition of cardiovascular complications and toxicity in CAR T-cell treatment and their manifestations. He discusses some retrospective analyses that tried to identify patients most at risk of developing these complications. Finally he outlines the risk factors for cardiovascular toxicities such as high disease burden and cytokine release syndrome.
More about...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox